IPM Take
The cardiometabolic drug race is beginning to move beyond GLP-1.
Roche has signed a strategic research collaboration with Atavistik Bio to discover small-molecule medicines against multiple cardiovascular, renal and metabolic targets. Atavistik will receive $70 million upfront, with up to $1.9 billion in research, development and commercial milestones, plus tiered royalties if resulting medicines reach the market. Atavistik Bio
The targets are undisclosed, and no candidate has entered development from the partnership. That makes this an early discovery signal, not evidence of a new treatment.
But the scientific direction matters.
Atavistik’s platform searches for allosteric pockets, binding sites away from the conventional active site of a protein. Those pockets can potentially allow more selective small molecules to modulate proteins that have proved difficult to drug through traditional approaches. The ambition is simple to state and difficult to execute: turn biologically important but therapeutically inaccessible targets into oral medicines. Atavistik Bio
For Roche, the deal also fits a much larger pattern. One week earlier, the company opened a Boston innovation centre dedicated to cardiovascular, renal and metabolic disease, bringing CVRM scientists together with data science and AI teams. Roche
The message is increasingly clear: Roche does not appear to be treating cardiometabolic disease as a single obesity market. It is building a broader discovery ecosystem around the biology that connects obesity, cardiovascular disease, kidney disease and metabolic dysfunction.
Executive Summary
Atavistik Bio and Roche announced a multi-target research collaboration on 24 September focused on cardiovascular, renal and metabolic disease. Atavistik will lead discovery and early research, while Roche will take responsibility for subsequent preclinical development, clinical development, regulatory activity and commercialisation. Atavistik Bio
The collaboration will use Atavistik’s proprietary AMPS platform, which identifies biologically relevant allosteric binding pockets and uses those findings to guide small-molecule design. Atavistik describes the platform as combining experimental screening with structure-based design, advanced data analysis and AI/ML-enabled chemistry. Atavistik Bio
The deal is heavily backloaded. Atavistik receives $70 million immediately, while the much larger $1.9 billion figure depends on future research, development and commercial milestones. No disease targets or clinical candidates have been publicly disclosed. Atavistik Bio
The partnership follows a series of investments that have expanded Roche’s CVRM footprint, including its acquisition of Carmot Therapeutics for $2.7 billion upfront in 2023 and its 2025 acquisition of 89bio, which brought the Phase III FGF21 analogue pegozafermin into its MASH portfolio. Roche
Why it matters
- HTA bodies: There is no near-term assessment implication because the collaboration remains at discovery stage. But novel mechanisms emerging from previously inaccessible targets could eventually challenge existing therapeutic comparators and treatment sequencing in CVRM disease.
- Payers: The strategic shift toward oral small molecules could matter if future candidates offer effective alternatives to more complex injectable or biologic therapies. Any cost advantage remains hypothetical until actual candidates, doses and clinical outcomes emerge.
- Industry / innovation partners: The deal reinforces a broader move toward platform-based drug discovery, where pharmaceutical companies pay for access to technologies capable of finding new chemistry around difficult biological targets rather than acquiring a single late-stage asset.
The obesity boom may have put cardiometabolic medicine at the centre of pharmaceutical strategy, but Roche’s latest deal is aimed at something much earlier than the next weight-loss drug.
The company is partnering with Cambridge, Massachusetts-based Atavistik Bio to search for new small-molecule medicines across cardiovascular, renal and metabolic disease.
Atavistik will receive $70 million upfront. The company could receive another $1.9 billion if research, development and commercial milestones are achieved, with royalties on any medicines that ultimately reach the market. Atavistik Bio
The headline number is therefore not the price Roche is paying today.
It is the maximum potential value of a discovery programme whose targets have not yet been disclosed.
What Roche is buying access to is Atavistik’s approach to allostery.
Traditional small molecules often bind to a protein’s active site. That works well when a suitable pocket exists and when blocking that site produces the desired biological effect. But many disease-associated proteins do not provide an obvious conventional binding site, or their active sites are difficult to target selectively.
Allosteric drugs take another route.
They bind elsewhere on the protein and alter how it behaves. Atavistik’s AMPS platform is designed to systematically identify these less obvious, sometimes cryptic, functional pockets and then use structure-based chemistry to develop selective molecules against them. Atavistik Bio
Atavistik says its discovery system combines experimental screening with computational approaches, advanced analytics and AI-enabled structure-based design. The company originally developed the approach around protein-metabolite interactions, using naturally occurring molecular regulation as a way to reveal new therapeutic binding sites. Atavistik Bio
The idea is scientifically attractive because selectivity matters.
A drug that modulates a disease-relevant protein through a distinct allosteric pocket could, in principle, influence pathological signalling while interfering less with related proteins or normal biological functions. Whether that advantage translates into better efficacy or tolerability has to be demonstrated candidate by candidate.
Atavistik does have a clinical-stage programme of its own. Its lead internal drug, ATV-1601, is an investigational oral allosteric AKT1-selective inhibitor in development for hereditary haemorrhagic telangiectasia. But the new Roche collaboration concerns separate, undisclosed CVRM targets. Atavistik Bio
For Roche, the partnership arrives during a deliberate expansion in cardiometabolic medicine.
On 17 September, the company opened the Roche Genentech Innovation Center Boston, describing it as a hub for cardiovascular, renal and metabolic research alongside data science and AI. The centre forms part of Roche and Genentech’s broader $50 billion US manufacturing and R&D investment plan. Roche
The company has also spent heavily on assets closer to patients.
Its $2.7 billion upfront acquisition of Carmot Therapeutics brought in clinical-stage incretin programmes for obesity and diabetes. Roche later acquired 89bio, adding the Phase III FGF21 analogue pegozafermin for MASH to its pipeline. Roche
That makes the Atavistik agreement different.
Roche is not buying another established cardiometabolic mechanism. It is paying for the possibility of discovering mechanisms that current chemistry cannot easily reach.
For the moment, there are no disclosed targets, no clinical candidates and no evidence that any resulting medicine will succeed.
But that uncertainty is precisely why the deal is a useful signal.
As competition intensifies around established incretin biology, some of the industry’s biggest bets are moving upstream, toward the question of what cardiometabolic biology can be drugged next.
